-
PARP Inhibitors in Pancreatic Cancer
Drugs that target DNA repair enzymes may provide alternatives to long-term chemotherapy for some patients with pancreatic cancer.
by Kate Yandell
-
The Crowded Field of Checkpoint Inhibitors
Drug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.
by Kate Yandell
-
Drug Costs and Cancer Care
Experts discuss the value of cancer treatments in a climate of rising drug prices.
by Kevin McLaughlin
-
What Is Hyper-Progression?
Some researchers believe that immunotherapy occasionally causes cancer to grow faster, a phenomenon dubbed hyper-progression.
by Kate Yandell
-
Risk Reduction, Clinical Trials Are Focus of Atlanta Community Event
Cancer researchers, patient advocates and community members gathered for a public forum presented by the American Association for Cancer Research.
by Kevin McLaughlin
-
March 29: The Week in Cancer News
Jury awards damages to man who says Roundup caused his cancer, the FDA proposes national standards for breast density notifications, and a physician questions whether patients with impaired renal function should avoid contrast-enhanced scans.
by Marci A. Landsmann
-
From the Editor-in-Chief
Why Are Liver Cancer Death Rates Up?Hepatitis C infection, obesity and alcohol can contribute to more cases of liver cancer.
by William G. Nelson, MD, PhD
-
Forward Look
Some Prostate Cancer Patients Face a Difficult DecisionSurgery and radiation have similar benefits but different side effects.
by Stephen Ornes
-
Forward Look
Looking for Brain MetastasesStudies aim to identify when screening is beneficial.
by Sue Rochman
-
Forward Look
Lynch Syndrome Linked to More CancersStudy findings suggest patient screening has been too narrow.
by Sharon Tregaskis
Cancer Talk
Treating Smoldering Multiple Myeloma
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona